1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
LidarCLIP or : How i Learned to Talk to Point Clouds
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
NeuRAD: Neural Rendering for Autonomous Driving
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
- Contribution to journal › Article
- 2023
-
Mark
Zenseact Open Dataset : A large-scale and diverse multimodal dataset for autonomous driving
(2023) 2023 IEEE/CVF International Conference on Computer Vision, ICCV 2023 In Proceedings of the IEEE International Conference on Computer Vision p.20121-20131
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
- Contribution to journal › Article
- 2018
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
- Contribution to journal › Article
- 2017
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
- Contribution to journal › Article
- 2016
-
Mark
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
- Contribution to journal › Article
- 2013
-
Mark
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
- Contribution to journal › Article
